SPARCSun Pharma Advanced Research Company Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.8 this quarter.
Momentum from moving averages, Supertrend and RSI.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
Forensic screen of the latest filings
Quality, growth, balance sheet and earnings quality behind the score
The reported figures could not be verified. They fail internal consistency checks, so the scores above should not be relied on.
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹30 Cr | ₹-24 Cr | -100.00% | -81.22% | ₹-0.75 | -50.0x |
| Q1 FY2027 | ₹40 Cr | ₹-21 Cr | -90.68% | -52.05% | ₹-0.64 | -1.5x |
| Q4 FY2026 | ₹1853 Cr | ₹1761 Cr | 95.55% | 95.04% | ₹54.27 | 152.3x |
| Q3 FY2026 | ₹8 Cr | ₹-80 Cr | -100.00% | -951.72% | ₹-2.48 | -8.2x |
| Q2 FY2026 | ₹8 Cr | ₹-76 Cr | -100.00% | -965.01% | ₹-2.34 | -9.1x |
| Q1 FY2026 | ₹10 Cr | ₹-52 Cr | -100.00% | -538.07% | ₹-1.60 | -7.4x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.